It is an Ad5‐based oncolytic vaccine engineered to express granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and replicate selectively in tumor cells with mutated or deficient retinoblastoma (Rb) protein. The gene discussed is RB1; the disease is neoplasm.